<DOC>
	<DOCNO>NCT00536198</DOCNO>
	<brief_summary>This study evaluate effectiveness sertraline reduce symptom woman diagnose premenstrual dysphoric disorder .</brief_summary>
	<brief_title>Evaluating Effectiveness Sertraline Treating Women With Premenstrual Dysphoric Disorder</brief_title>
	<detailed_description>Premenstrual dysphoric disorder ( PMDD ) severe form premenstrual syndrome ( PMS ) . PMDD affect nearly 5 percent menstruate woman United States . This disorder disruptive affect woman 's performance work relationship friend family . Symptoms typically occur 10 14 day start woman 's period dissipate soon . Sadness , rapid change mood , anxiety , irritability common symptom associate PMDD . Sertraline selective serotonin reuptake inhibitor ( SSRI ) approve U.S. Food Drug Administration ( FDA ) treat PMDD . This study evaluate effectiveness sertraline reduce symptom woman diagnose PMDD . All participant begin study record symptom two complete menstrual cycle . At baseline study visit , participant randomly assign receive either sertraline placebo six menstrual cycle . At onset PMDD symptom , participant take two pill assign treatment daily . Once symptoms dissipate , usually around first second day menstrual cycle , participant stop take assign treatment cycle . For next 4 month , participant attend study visit fifth day monthly menstrual cycle . For follow 2 month , participant contact telephone . Participants ask rate mood symptom contact . A final study visit schedule first day seventh menstrual cycle . At point , participant offer sertraline additional three menstrual cycle , dose daily basis . Two study visit schedule course three cycle evaluate effectiveness sertraline dose continuously . Urine collection pregnancy test may occur select time study .</detailed_description>
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Menstruating cycle 21 35 day Meets DSMIV criterion PMDD Experienced symptom PMDD least 9 12 menstrual cycle within 1 year study entry Willing use effective form birth control throughout study Meets MINI DSMIV criterion major depressive episode , substance abuse , bulimia nervosa , anorexia , bipolar disorder , psychotic disorder , schizophrenia schizoaffective disorder , within 6 month study entry Meets MINI DSMIV criterion substance dependence disorder within 12 month study entry Shows follicular phase symptom consistent diagnosis major depression Shows symptom consistent bipolar disorder Diagnosed severe , clinically significant coexist condition may prevent study participation Suicidal Taking ongoing antidepressant psychotropic medication History hypersensitivity adverse reaction sertraline Pregnant breastfeed Currently undergo treatment depot hormonal preparation medication would lead lack menses markedly irregular menses Using hormonal contraceptive pill hormonal device within 6 month study entry Taking hormonal contraceptive pill include 20 microgram ethinyl estradiol 3 microgram drospirenone Has individual psychotherapy individual counsel 3 month less study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Premenstrual Syndrome</keyword>
</DOC>